According to a head-to-head randomized controlled trial, FLUBLOK QUADRIVALENT was proven to provide better protection versus a standard-dose quadrivalent inactivated influenza vaccine1,2:
b PCR = Polymerase chain reaction.
INDICATION FOR FLUBLOK QUADRIVALENT VACCINE
Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.
SIMILAR SAFETY PROFILE in adults 50+ (N=4,312) compared with a standard-dose quadrivalent inactivated influenza vaccine (N=4,327)1
Two separate studies in adults showed that rates of local and systemic adverse reactions were similar among Flublok Quadrivalent and Fluarix® Quadrivalent recipients1
AN INFLUENZA VACCINE WITH A UNIQUE COMPOSITION
- 3X more hemagglutinin antigen versus a standard-dose quadrivalent inactivated influenza vaccine3
- Similar safety profile compared to a standard-dose inactivated influenza vaccine2
Made with RECOMBINANT DNA
- Eliminates the need to grow influenza virus during manufacturing, which ensures hemagglutinin antigen cannot adapt or mutate
- Avoids changes in hemagglutinin antigen structure that can lead to reduced vaccine effectiveness
Recombinant DNA Technology Avoids Antigenic Adaptations and Mutations2
b WHO = World Health Organization.